



Preparations for **HIV Vaccine Research** at Zambia-Emory HIV Research Project (ZEHRP)



William Kilembe¹, Susan Allen^{1,2}, Elwyn Chomba³, Cheswa Vwalika¹,
Shabir Lakhi^{1,3}, Olivier Manigart¹, Patricia Fast⁴, Claudia Schmidt⁴, Fran
Priddy⁴, Wendy Komaroff⁴ Matt Price⁴

- 1 Zambia Emory HIV Research Project (ZEHRP)
2. Emory University School of Public Health
3. University Teaching Hospital (Lusaka, Zambia)
4. International AIDS Vaccine Initiative (IAVI)




Overview of ZEHRP



- ZEHRP was established in 1994 in Lusaka with the aim of providing Couple VCT.
- 3 Couples VCT sites in Lusaka and other sites on the Copper-belt Province (Kitwe and Ndola) and in Southern Province (Mazabuka).
- HIV Discordant, cohabiting couples who reside in Lusaka and the Copper belt are invited to enroll in ongoing research studies
- Couples are followed at least quarterly and provided with risk reduction counseling and supplied with condoms to prevent HIV transmission to the negative partner.
- determine Virologic and immunologic correlates of HIV transmission if transmission occurs in spite of risk reduction counseling



ZEHRP sites





Objectives



Main Objective:

- To carry out research aimed at prevention of HIV infection and development of a safe and efficacious HIV Vaccine.

Specific Objectives:

- To adequately train staff and prepare site for clinical trials
- To establish baseline characteristics of study population
- To provide accurate information to potential trial participants
- To recruit and retain vaccine trial participants
- To expand cohort of HIV discordant couples for future vaccine trials in at risk individuals



Training of staff



- Local requirements- attend Good Clinical Practice (GCP) and Good Clinical and Lab Practice (GCLP)
- All of the staff also completed Collaboration IRB Training Initiative (CITI) course for human rights protection and are expected to renew every two years
- DAIDS policy training e.g. Expedited Adverse Event (EAE) training.
- Clinic staff trained on Basic Life Support



Staff training on Basic Life Support

GCP and GCLP training



Infrastructure development:



Development of an additional site where vaccine trials are co-ordinated

- Internationally accepted laboratory standards
- Pharmacy for vaccine storage and preparation has been put in place



Protocol D



- Protocol D was a cross sectional observational study to establish Clinical Laboratory reference values
- 400 healthy HIV negative individuals (200 males and 200 females) between 18 and 60 years of age were recruited from Couples VCT and discordant couple cohort and enrolled into the study.
- Study close out for all participating sites was March 2007.




Present and Future HIV Vaccine Trials



A002

400 enrolled in Protocol D



A002

A Phase II Placebo-controlled double-blind trial to evaluate safety and immunogenicity of tgAAC09, an HIV Vaccine containing Clade C gag-PR-ΔRT DNA In An Adeno-Associated Virus (AAV) Capsid, Administered twice, at Three Dosage Levels and Two Dosing Intervals.

Enrolled = 16

Preparation for future vaccine trials

Couples Voluntary Counseling and Testing (CVCT) Centers

Mobile CVCT



Discordant Couples Cohort

HIV negative partners



Information Sessions including
- basic clinical research concepts
- information on HIV vaccines
- effective contraception and circumcision



V002

A Phase II, Randomized, Placebo-Controlled Double blind trial to evaluate the Safety and immunogenicity of a Multi-clade HIV- 1 DNA Plasmid Vaccine followed by Recombinant, Multi-clade HIV-1 Adenoviral vector Vaccine in Healthy adults volunteers at Risk for HIV Infection

PAVE 100

A Phase IIB Randomized, Placebo-Controlled, International Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of a Multi-clade HIV-1 DNA Plasmid vaccine, RC-HIVDNA016-VP, Followed by a Multi-clade Recombinant Adenoviral Vector Vaccine VRC-HIVADV014-00-VP, in participants at Risk for HIV-1 infection



Lessons Learnt



- Enrolling participants from existing cohorts into vaccine trial is a good strategy to improve retention and follow up rates.
- Collection and update of locator information (i.e. Address and telephone numbers of participants) has assisted greatly in follow up of participants.
- Experience gained and lessons learnt from the previous smaller vaccine trial will help with upcoming larger trials.
- Information sessions given in form of focus group discussion have facilitated the informed consent process at screening visits



Lessons Learnt(2)



- Information sessions have allowed enough time for potential participants to decide about their choice to participate or not
- Information sessions have also helped the study site staff to identify which concepts of HIV vaccine clinical trials need emphasis to aid understanding
- Involvement of the Community Advisory Board has helped a great deal in ensuring cooperation from participants



Future perspectives



- **Expansion to involve 2 new clinical trial sites in the Copper-belt for the upcoming vaccine trials to be conducted in Lusaka and the Copper-belt.**
- **Ramp up of Couples VCT activities to increase cohort of discordant couples:**
 - **Mobile Units to provide CVCT**
 - **Expansion of CVCT to district clinics in Lusaka**
 - **Revert to old system of providing CVCT at sites 6 days a week instead of the current 3 days (once maximum capacity is reached during the current 3 days)**
 - **Training and enrolling new Influential Network Agents (INAs)**



Acknowledgments:



1. Rwanda Zambia HIV Research Group (RZHRG)
2. Emory University Centers for AIDS Research (CFAR) and Fogarty AIDS International Training in Research (AITRP) Programs
3. Targeted Genetics Corporation (TGC)
4. Philip Johnson, MD, Children's Hospital of Philadelphia (CHOP) and & The Research Institute, Nationwide Children's Hospital



iavi International AIDS Vaccine Initiative

IAVI gratefully acknowledges the generous support provided by the following major donors.*



Provided with the support of the European Union



Canadian International Development Agency

Agence canadienne de développement international



Alfred P. Sloan Foundation
 Basque Autonomous Government
 Becton, Dickinson and Company (BD)
 Bill & Melinda Gates Foundation
 Broadway Cares/Equity Fights AIDS
 Canadian International Development Agency
 Continental Airlines
 Crusaïd
 Deutsche AIDS-Stiftung
 European Union
 Google Inc.
 The Haas Trusts
 Irish Aid
 The John D. Evans Foundation
 Kathy Bole & Paul Klingenstein
 Merck & Co., Inc.

The Netherlands Ministry of Foreign Affairs
 The New York Community Trust
 Norwegian Royal Ministry of Foreign Affairs
 Pfizer Inc
 The Rockefeller Foundation
 Royal Danish Ministry of Foreign Affairs
 The Starr Foundation
 Swedish International Development Agency
 Swedish Ministry of Foreign Affairs
 U.K. Department for International Development
 Until There's a Cure Foundation
 The U.S. President's Emergency Plan for AIDS Relief through the U.S. Agency for International Development
 The World Bank/Global Forum for Health Research



USAID
 FROM THE AMERICAN PEOPLE



THE WORLD BANK



REGERINGSKANSLIET
 Ministry for Foreign Affairs
 Sweden

And many other generous individuals from around the world.

* As of 11/06

